Objective-Eicosapentaenoic acid (EPA) has been shown to have beneficial effects on cardiovascular diseases, although the precise mechanism is unknown. We investigated the effect of EPA on the regression of atherosclerosis. Methods and Results-LDL-receptor-deficient mice were fed a high-cholesterol diet for 8 weeks to build up aortic sinus atherosclerotic lesions and then were fed a normal diet with or without 5% EPA for 4 weeks. Atherosclerotic lesions were histologically assessed, and immunologic assays were performed. EPA treatment significantly regressed atherosclerosis (Ϫ22.7%, PϽ0.05) and decreased the content of macrophages, CD4 ϩ T cells, and dendritic cells (DCs) in atherosclerotic lesions, though only changing the chow never induced the regression. Flow cytometric analysis revealed that EPA increased immature DCs (CD11c ϩ CD80 Ϫ CD86 Ϫ ), increased the indoleamine 2,3-dioxygenase (IDO) in DCs, and decreased the number of CD4 ϩ T cells. In the presence of the IDO inhibitor, the beneficial effects of EPA on regression were inhibited, suggesting that the effect of EPA was mainly mediated through IDO. 
vidence for atherosclerosis regression in humans has been reported. 1, 2 Although lowering of plasma lipid levels is a major driving force, the mechanisms that promote lesion regression are not clear. Recent clinical evidence indicated that lowering elevated high-sensitive C-reactive protein levels in plasma with 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) significantly reduced the incidence of major cardiovascular events in normolipidemic healthy persons. 3 These data indicate that statins, in addition to their aggressive lipid lowering effect, may also be a hopeful therapeutic strategy for inhibiting cardiovascular events via stabilization or regression of atherosclerotic plaques through their antiinflammatory actions.
See accompanying articles on page 1939 and 1943
Eicosapentaenoic acid (EPA), a long-chain n-3 fatty acid, was reported to have beneficial effects on cardiovascular diseases. 4, 5 We have also demonstrated that the use of highly purified EPA, in addition to statins, prevented cardiovascular events in Japanese hypercholesterolemic patients. 6 On the basis of these findings, we hypothesized that EPA could regress atherosclerosis. Recent studies demonstrated that a metabolite of EPA inhibited the maturation of dendritic cells (DCs), downregulated costimulatory molecules, and induced indoleamine 2,3-dioxygenase (IDO). 7 IDO, an enzyme involved in tryptophan catabolism, breaks down tryptophan required for T cell proliferation, and its induction is associated with T cell immune suppression. 8, 9 Here, we investigated the effects of highly purified EPA in an atherosclerosis regression mouse model. The present results indicate that the intervention to inflammatory responses, such as the induction of tolerogenic DCs, could be therapeutic methods for atherosclerotic plaque regression. A better understanding of the underlying mechanisms involved in atherosclerosis regression will allow us to develop novel therapeutic interventions to enhance plaque regression and reduce cardiovascular events.
Methods
Please see the Online Appendix for a detailed description of Methods, available at http://atvb.ahajournals.org.
Animals and Experimental Design
Low-density lipoprotein receptor knockout (LDLR Ϫ/Ϫ ) mice were kept in a specific pathogen-free animal facility at Kobe University Institute. All animal experiments were conducted according to the Guidelines for Animal Experiments at Kobe University School of Medicine. Six-week-old male LDLR Ϫ/Ϫ mice received a high-fat and cholesterol diet (21% fat, 1.25% cholesterol, and 0.5% cholate; Oriental Yeast, Tokyo, Japan) for 8 weeks. At 14 weeks of age, their diet was changed to fish powder-free diet with or without 5% ultrapure EPA ethylester (Ͼ99% purity; Mochida Pharmaceutical Co, Ltd, Tokyo, Japan) and continued until euthanized. In several experiments, mice were treated with the IDO inhibitor (1-methyl-DL-tryptophan, 1-MT; Sigma, St. Louis, MO) 10 or its solvent. Mice were euthanized at 14, 16, 18, and 22 weeks of age, and atherosclerotic lesions were assessed as previously described. 11
Cell Isolation and Flow Cytometry Analyses

Purified CD11c
ϩ DCs and CD4 ϩ T cells were isolated from mesenteric lymph nodes (LNs) and spleens using an AutoMACS separator (Miltenyi Biotec, Inc, Auburn, CA) according to the manufacturer's instructions and were used for flow cytometry analyses, cell culture experiments, and total RNA extraction.
Assessment of mRNA Expression
Total RNA was extracted from CD11c ϩ DCs and mouse aortic roots after perfusion with RNAlater (Ambion, Austin, TX) using TRIzol reagent (Invitrogen, Carlsbad, CA). Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) was performed as described previously. 11
Statistical Analysis
Data were expressed as meansϮSEM. Mann-Whitney U test was used to detect significant differences between two groups. KruskalWallis test was used to detect significant differences when 3 groups were compared. Statistical values of PϽ0.05 were considered statistically significant.
Results
EPA Induces Regression of Established Atherosclerotic Lesions
Our original regression mouse model and the design of experiments presented here are outlined in Figure 1A . In brief, 6-week-old LDLR Ϫ/Ϫ mice were fed a high-cholesterol and high-fat diet for 8 weeks to build up atherosclerotic lesions at the aortic sinus. When mice were 14 weeks old, the diet was changed to normal food with (EPA) or without 5% EPA (control) and continued for 4 weeks. Changing the diet markedly reduced plasma cholesterol levels as shown in Table. Orally administered EPA further decreased plasma cholesterol levels as previously observed. 12 For baseline levels, atherosclerosis was assessed when mice were 14 weeks (baseline; 5.50Ϯ0.46ϫ10 5 m 2 ) and 18 weeks old for each group ( Figure 1B and 1C) . There was no observable decrease in plaque area in mice who were switched to the normal diet at 18 weeks of age (control; 5.38Ϯ0.33ϫ 10 5 m 2 ) or at 22 weeks of age ( Figure 1C ). Addition of EPA to the normal diet normalized plasma cholesterol and significantly regressed established atherosclerosis at 18 weeks of age (EPA; 4.25Ϯ0.33ϫ10 5 m 2 ; Ϫ22.7% versus baseline and Ϫ20.9% versus control, PϽ0.05; Figure 1B and 1C), although further EPA treatment for 4 weeks showed no additional effects. As EPA significantly reduced plasma cholesterol level, we examined EPA-treated group with adjusted plasma cholesterol level to control group to rule out the effect of lowering cholesterol on the regression. As shown in Supplemental Figure I , EPA could induce the regression compared with control group even under the same plasma cholesterol condition.
Qualitative Analyses of Atherosclerotic Plaques Before and After Regression
Immunohistochemical analysis of the aortic root (baseline, control, and EPA) was performed to determine changes in atherosclerotic plaques before and after regression. Macrophage accumulation and CD4 ϩ T cell content was markedly decreased with EPA treatment compared with those in the baseline and control groups ( Figure 1D and 1E). In addition, smooth muscle cell content, as determined by ␣-smooth muscle actin staining and collagen content assessed by Masson Trichrome staining, was increased by EPA compared with those in the baseline and control groups ( Figure 1D and 1E) .
Next, we performed the assays focusing on DCs in atherosclerotic lesions. CD86 is recognized as an important costimulatory molecule related to maturation of DCs. We examined the number of CD11c ϩ and CD11c ϩ CD86 ϩ mature DCs using immunohistochemical studies, and mRNA expression of CD11c and costimulatory molecules with quantitative RT-PCR in atherosclerotic lesions. Lowering cholesterol significantly reduced the number of DCs, and EPA further markedly decreased both the number of DCs and the expression of costimulatory molecules (Figure 2A) . The same observation applied to the mRNA expression of CD11c and costimulatory molecules ( Figure  2B ). Taken together, these results indicate that EPA decreased the number of mature DCs in the plaque at 18 weeks. To assess the mechanism of regression of the atherosclerotic plaque, we examined mRNA expression of cytokines, chemokines, matrix metalloproteinases (MMPs), and adhesion molecules in atherosclerotic plaques by quantitative RT-PCR ( Figure 2C ). We found that proinflammatory cytokines and chemokines, such as interferon (IFN)-␥, interleukin (IL)-12p40, monocyte chemoattractant protein (MCP)-1, and tumor necrosis factor (TNF)-␣, were significantly reduced in the EPA group compared with those in the baseline or control groups. MMPs, which degrade the extracellular matrix, were also reduced in the EPA group. On the other hand, the levels of the antiinflammatory cytokine transforming growth factor (TGF)-␤ were increased, but IL-10 levels were decreased in the EPA group. Levels of adhesion molecules such as intracellular adhesion molecule (ICAM)-1 were reduced in the EPA group compared with those in the baseline or control groups, but vascular cell adhesion molecule (VCAM)-1 levels were not affected by EPA treatment. 
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Effect of EPA on DCs in Systemic Lymphatic Organs
We performed flow cytometry analyses using CD11c ϩ DCs from spleens and LNs after positive selection with antiCD11c microbeads in each group and found that CD11c ϩ DCs in the EPA group expressed lower levels of CD80, CD86, CD40, and major histocompatibility complex class II compared with levels in the control groups ( Figure 3A , 3B, and 3C). We also confirmed another maturation marker CD83 was reduced in EPA group (data not shown). These results indicate that EPA systemically induces immature DCs characterized by low expression of costimulatory molecules. We assessed the expression of IDO in CD11c ϩ DCs by flow cytometry analysis. IDO is an enzyme that catabolizes the amino acid tryptophan and plays an important role in T cell proliferation and apoptosis. 9 We observed significant increase in IDO expression in CD11c ϩ DCs from EPA-treated mice compared with those from the baseline and control groups (PϽ0.05; Figure 3D ). We next examined whether the DCexpressed IDO from EPA-treated mice was functional. IDO activity assessed by the levels of kynurenine, a metabolite of tryptophan, in the culture supernatant of DCs from spleens indicated higher values in EPA-treated group than that in the baseline or control group (PϽ0.01; Figure 3E ). We also 
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Arterioscler Thromb Vasc Biol September 2011 ϩ DCs of baseline (black shaded area), control (gray area), and EPA (under blue line area) is shown. B and C, Quantitative analysis of surface expression for each marker was determined as mean fluorescence intensity (MFI). nϭ5 in baseline, nϭ7 in control, and nϭ7 in EPA group. D, Cells from spleens and LNs of 14-week-old (baseline) and 18-week-old (control and EPA) mice were prepared, stained with fluorescein isothiocyanate-conjugated anti-CD11c and anti-indoleamine 2,3-dioxygenase (IDO) antibody followed by allophycocyanin-labeled secondary antibody, and assessed by flow cytometry. The histograms were gated on CD11c ϩ DCs. Quantitative analysis of expression for IDO was determined as MFI. nϭ4 in baseline, nϭ7 in control, and nϭ7 in EPA group. E, The IDO activity was assessed by kynurenine production in the culture supernatant of CD11c ϩ DCs isolated from spleens of each group, which were incubated in Hanks balanced salt solutions for 8 hours. nϭ4 per group. F, Total RNA was extracted from CD11c ϩ DCs isolated from spleens of each group. Expressions of interleukin (IL)-6, IL-12p40, IL-10, transforming growth factor (TGF)-␤ were quantified by quantitative real-time reverse transcription polymerase chain reaction and normalized to glyceraldehyde 3-phosphate dehydrogenase. Fold changes relative to each baseline group are shown. nϭ6 per group. *PϽ0.05 and **PϽ0.01 vs control. #PϽ0.05 and ##PϽ0.01 vs baseline.
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assessed mRNA levels of DC-associated cytokines in CD11c ϩ DCs from spleens and found a significant decrease in mRNA levels of proinflammatory cytokines IL-6 and IL-12p40 compared with control, whereas mRNA levels of antiinflammatory cytokines IL-10 and TGF-␤ were upregulated in the EPA group ( Figure 3F ). Therefore, we could say that oral administration of EPA makes the phenotype of DCs immature and tolerogenic in vivo.
Effect of EPA on T Lymphocytes in Systemic Lymphatic Organs
Next, we investigated the effect of EPA on T cells. Orally administered EPA decreased the number of CD4 ϩ T cells in spleens and LNs ( Figure 4A ). DCs with immunosuppressive properties have less capacity to induce T cell proliferation. We performed in vitro proliferation assays of CD4 ϩ T cells from Balb/c mouse spleens cocultured with and stimulated by CD11c ϩ DCs from spleens of each group ( Figure 4B ). CD4 ϩ T cell proliferation was suppressed when cocultured with DCs from the EPA group compared with DCs from the baseline or control groups (PϽ0.05), suggesting that DCs from EPA-treated mice had less proliferation activity of T lymphocytes. To determine whether EPA directly contributes to the suppressive potential of lymphoid cells, we performed an in vitro proliferation assay of CD4 ϩ T cells from spleens after positive selection with anti-CD4 antibody in each group in response to anti-CD3/anti-CD28 antibodies. As shown in Figure 4C , ϩ lymphocytes from spleens and lymph nodes (LNs) of 14-week-old (baseline) or 16-and 18-week old (control and EPA) mice were prepared, stained with FITC-conjugated anti-CD4, and counted by flow cytometry. nϭ4 at 14 weeks old and nϭ5 at 18 
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we observed no reduction in CD4 ϩ T cell proliferation in the EPA group compared with that in the control group. It is unlikely that EPA directly suppresses T cell proliferation. Tolerogenic DCs have been previously shown to inhibit T cell proliferation through the induction of Tregs. 13 Most Tregs are characterized by CD25 and Foxp3 expression and, for some subsets, by increased IL-10 or TGF-␤ production. 14 We observed no increase in CD25 or Foxp3 expression in the CD4
ϩ T cell population in spleens and LNs of EPA-treated mice at 18 weeks ( Figure 4D ). To assess whether EPA induces the apoptosis in T cells or not, we investigated the annexin V assays. There was no difference in the expression of annexin V in splenocytes and LN cells between the two groups ( Figure 4E ). Previous studies have shown that DCs generated in the presence of EPA metabolites are poor stimulators of activated T cells but do not induce CD4 ϩ Foxp3 ϩ T cells. 7 As such, our data imply that tolerogenic DCs induced by EPA treatment may systemically suppress activated immune reactions without inducing Tregs. Further, to determine the effects of EPA on the activation of T lymphocytes in vivo, we examined the surface expression of the activation marker CD44 high and CD62L
low by flow cytometry analysis. These activation markers on T cells were not changed or slightly increased in EPA-treated mice compared with controls ( Figure 4F ). Next, to determine whether EPA-treatment affects the cytokine production from T cells, we analyzed IFN-␥, IL-4, IL-10, and IL-17 production or expression by intracellular cytokine staining. We could not detect any differences in the ex vivo cytokine production from T cells of spleens among the three groups ( Figure 4G ). Taken together, EPA might not directly affect the function of T cells in vivo but inhibited T cell proliferation via DCdependent manner and resulted in decreasing the number of T cells.
Role of IDO in the Beneficial Action of EPA
To determine whether IDO expressed in DCs is directly involved in regression of established atherosclerotic plaques after EPA treatment, we treated mice with an IDO inhibitor, 1-MT, which blocks the function of IDO. 10 Administration of 1-MT significantly increased atherosclerotic lesions ( Figure 5A and 5B), macrophage contents, and CD4 ϩ T cell contents (Supplemental Figure IIA and IIB) in the EPA-treated group compared with the solventtreated EPA group, although 1-MT never affected plasma cholesterol levels (Table) . In the presence of 1-MT, there were no significant differences in atherosclerotic lesions between the EPA and control groups. 1-MT treatment did not significantly affect the IDO expression in DCs ( Figure  5C ). The IDO activity was assessed by the kynurenine production in the culture supernatant of DCs from spleens of each group. 1-MT treatment significantly decreased the kynurenine level in DCs only in EPA group ( Figure 5D ). We found that the number of CD4 ϩ T cells was significantly increased in spleens and LNs in the presence of 1-MT ( Figure 5E ). There were no differences in DCmediated T cell proliferation between 1-MT-treated control and 1-MT-treated EPA groups (Figure 5F ), suggesting 1-MT treatment could partly cancel the effect of EPA on DC-mediated T cell proliferation. These results suggest that the beneficial effects of EPA on the regression of atherosclerosis in this model were mediated at least in part by IDO. Moreover, inhibition of T cell proliferation was mainly dependent on the activity of IDO likely expressed in DCs.
Discussion
The major findings of the present study are as follows: (1) EPA administration to mice with normalized plasma cholesterol levels induced regression of atherosclerosis in LDLR Ϫ/Ϫ mice over a 4-week period, and (2) we demonstrated a possible mechanism associated with the regression of atherosclerosis. Increasing IDO expression in DCs is highly associated with regression, and decreasing the number of CD4 ϩ T lymphocytes is another therapeutic candidate to induce atherosclerosis regression.
Epidemiological and clinical evidence suggests an increased intake of EPA protects against death from coronary artery disease. 4, 5 We demonstrated that additive EPA treatment with statins reduced the frequency of major coronary events without affecting plasma lipid values. 6 To provide a molecular mechanism for the epidemiological evidence, several animal studies have demonstrated the antiatherogenic effects of EPA. Matsumoto et al demonstrated that EPA reduced progression of atherosclerotic lesions in apolipoprotein E-deficient mice through its antiinflammatory effects, including attenuation of some adhesion molecules and chemokines. 12 Another article indicated that a high content of dietary long-chain n-3 fatty acids minimizes atherosclerosis and inflammatory responses in LDLR Ϫ/Ϫ mice. 15 On the basis of these findings, we investigated the effect of EPA treatment with normalized plasma cholesterol levels on atherosclerotic plaques in LDLR Ϫ/Ϫ mice. We demonstrated for the first time that EPA treatment results in a rapid regression of atherosclerosis, supporting the clinical beneficial effects of EPA on secondary prevention of cardiovascular diseases in patients. Transfer of high-fat and cholesterol-fed LDLR Ϫ/Ϫ mice to a normal diet stopped further progression of atherosclerosis and led to a less inflammatory plaque phenotype, but it was not sufficient to induce the regression of aortic sinus lesions. In contrast, a marked reduction in aortic plaque area was found in EPA-treated mice, suggesting that EPA facilitated the net removal of inflammatory cells and lipids probably due to antiinflammatory actions and increase in reverse cholesterol transfer. In the present study, we demonstrated that the number of infiltrated cells and mRNA expression of several chemokines, cytokines, and adhesion molecules were significantly reduced in atherosclerotic lesions in EPA-treated mice.
An in vitro study by Wang et al demonstrated that EPA inhibited LPS-induced DC maturation, decreased IL-12 and TNF-␣ levels, and reduced T cell stimulatory capacity. 16 IL-12 induces IFN-␥ production and is involved in the differentiation of T cells into potent type 1 helper T cells. 17 In this study, we found that EPA systemically reduced the maturation of DCs (expression of CD80,
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CD86, CD40, and major histocompatibility complex class II) and induced tolerogenic DCs, which was characterized by low expression of costimulatory molecules, less T cell stimulatory capacity, and minimal secretion of IL-12 in vivo. We also demonstrated that EPA markedly decreased the number of mature DCs in atherosclerotic plaques and DC-releasing material of plaques quantified by real-time RT-PCR as compared with the control. Although several research groups examined and reported the role of DCs in atherogenesis, it has been undefined yet. 18 Some investigators showed the role of DCs in the cholesterol metabolism 19 or in antigen presentation in the pathogenesis of atherosclerosis. 20 We also demonstrated the possibility that the inhibition of DC maturation reduced the formation of atherosclerosis, previously. 21 Taken together, we hypothesized that EPA may change the phenotype and function of DCs, and induce the regression of atherosclerosis.
Vassiliou et al demonstrated that a metabolite of EPA inhibited T cell proliferation through increasing IDO expression in DCs. 7 IDO is an enzyme involved in tryptophan catabolism. IDO breaks down tryptophan, which is necessary for T cell growth, resulting in the inhibition of T cell proliferation by inducing cell cycle arrest. 8, 9 Intriguingly, we detected an increase in IDO expression in DCs from the spleen and LNs of EPA-treated mice in vivo and demonstrated that the IDO enzyme activity, assessed by the production of kynurenine (a metabolite of tryptophan), was also increasing. In particular, IDO expression in DCs was indispensable for atherosclerotic plaque regression because administration of an IDO inhibitor canceled the beneficial effects of EPA and increased inflammatory cell infiltration and plaque formation to the extent of control with IDO inhibitor. We showed that EPA reduces the maturation of 
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DCs and increases IDO expression in DCs resulting in decreased numbers of CD4 ϩ T lymphocytes in vivo. Recent work has demonstrated that natural Tregs, which show high expression of CD25 on their surface and express the transcription factor Foxp3, play a protective role in atherogenesis in mice. 22, 23 Several articles demonstrated the relationship between IDO expression in DCs and the generation of Tregs. 8, 13 In this study, we found that CD4 ϩ
CD25
ϩ Foxp3 ϩ Tregs were not increased in spleens and LNs of EPA-treated mice, although IDO expression in DCs was increased. EPA was shown to inhibit T cell activation through a reduction in IL-12 secretion, which is critical for T cell proliferation and modification of the membrane lipid profile. 24 It is possible that Tregs are not involved in rapid atherosclerotic plaque regression, at least in this model. Moreover, it is unlikely that the apoptosis is a cause of the reduced number of CD4 ϩ T cells in EPA group. We demonstrated that T cell activation assessed by anti-CD3/ anti-CD28 antibodies induced proliferation, surface markers, and cytokine production was not inhibited in EPA group. On the other hand, we also verified that DCmediated T cell proliferation was significantly inhibited in EPA-treated group compared with that of control group, suggesting the inhibitory effects on the T cell proliferation was dependent on changes in phenotypes of DCs. Taken together, based on our experiments associated with T lymphocytes, EPA might not directly change the function of T cells but reduced the number of T cells possibly through the functional changes in DCs.
Systemic reduction of CD4 ϩ T cells via induction of tolerogenic DCs is proposed to be involved in rapid plaque regression. An IDO-inhibitor administration canceled the beneficial effects of EPA, rather significantly progressed atherosclerotic lesion with increasing the number of CD4 ϩ T cells compared with the baseline group. The results of our experimental study clearly indicate the critical role of CD4 ϩ T cells in the pathogenesis of atherosclerotic plaque regression. Systemic changes in immune responses are crucial determinants of atherosclerotic plaque progression. 25 Activated DCs might migrate from the vessel wall to secondary lymphatic tissues, where they interact with other immune cells. 26 On the basis of our observed findings, rapid systemic changes to antiinflammatory responses involved in tolerogenic DCs are also crucial determinants of atherosclerotic plaque regression. In the therapeutic harnessing of their inherent tolerogenicity on transplantation, considerable insight has been gained into the role of DC subsets in central and peripheral tolerance, and into the molecular pathways that regulate the outcome of DC-T cell interactions. 13 Results from our data are the first to demonstrate a possible role of a decrease in CD4 ϩ T cells via induction of tolerogenic DCs in rapid atherosclerotic regression, although further studies are required to provide more direct evidence for the interaction between T cells and DCs in plaques.
Recent vigorous examination using a mouse regression model revealed that several candidate molecules and markers are associated with lesion regression. Fisher et al demonstrated that elimination of foam cells, in addition to normalizing the plasma cholesterol levels, is critical to achieve atherosclerosis regression. 27 They raised the intriguing possibility that during regression, macrophage foam cells acquire DC characteristics that permit them to migrate to lymph nodes. In addition, it has been reported that lesion macrophages require intact chemokine receptor 7 (CCR7) signaling, an essential factor for DC migration, to migrate from atherosclerotic plaques under regressive conditions. 28 They also showed that mRNA levels of cholesterol efflux factors such as adenosine triphosphate-binding cassette transporter A1 (ABCA-1) were increased, and expression levels of VCAM-1 and MCP-1 were reduced in the plaque during regression. Unlike previous studies, we did not observe higher expression levels of CCR7 or ABCA-1 in the atherosclerotic plaques of the EPA group compared to the control group (data not shown), which may be due to the differences in the model, mouse background, the type of lesion, or timing of assessment, although further studies are required.
In conclusion, we showed that EPA treatment with normalizing plasma cholesterol can induce a rapid and substantial regression of atherosclerotic lesions, possibly mediated by changing the function of DCs and decreasing the number of T-lymphocytes. Our studies also imply the possibility that intervention of immune systems could be a novel therapeutic target for regression of atherosclerosis. EPA has been shown to reduce the incidence of cardiovascular events in humans, and the present findings might partly explain the beneficial effects of EPA in clinics and support the clinical evidence, although care should be taken when interpreting experimental results in mice. Atherosclerotic plaque regression should represent a therapeutic goal in the management of ischemic heart disease. Further studies are needed to clarify the molecular mechanisms of atherosclerosis regression.
